2008 Licensing Therapies 
New Drug Approvals
APRIL 19, 2025
New Drug Therapy Approvals 2024 (PDF). “Metoprolol Therapy and CYP2D6 Genotype” In Pratt VM, McLeod HL, Rubinstein WS, et al. . ^ Jump up to: a b c d [link] ^ “List of nationally authorised medicinal products Active substance: landiolol” (PDF). Procedure no.: PSUSA/00010570/201802. Retrieved 12 October 2024.
Drug Target Review
FEBRUARY 28, 2024
Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
New Drug Approvals
JUNE 26, 2025
Ma S, Gisselmann G, Vogt-Eisele AK, Doerner JF, Hatt H (October 2008). Prospects for prostate cancer imaging and therapy using high-affinity TRPM8 activators. 2008 Oct;21(4):370-8. 3] It is slightly less potent as a TRPM8 activator compared to icilin , but is a much more selective TRPM8 ligand when compared to menthol. [4]
The Pharma Data
MARCH 2, 2021
Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. Our mission is to create breakthrough therapies that change lives. Financial terms of the new agreement are not disclosed.
NIH Director's Blog: Drug Development
JUNE 14, 2016
The study, which analyzed vast troves of genomic and clinical data collected over many years from more than 50,000 people with and without diabetes, indicates that anti-diabetes therapies that lower glucose by targeting the product of a specific gene, called GLP1R , are unlikely to boost the risk of cardiovascular disease. December 2008. [2]
The Pharma Data
NOVEMBER 5, 2020
Velders is presently chairman of HollandBIO, the association of Dutch biotech companies, and provides years of experience, specifically in the cell and gene therapy areas. Taveras will lead all research and non-clinical development functions supporting the company’s pipeline of investigational therapies.
The Pharma Data
FEBRUARY 25, 2021
Food and Drug Administration (FDA) accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac , its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals 1 year of age and older. Tick-borne encephalitis virus in wild rodents in winter, Finland, 2008-2009.
Expert insights. Personalized for you.
Let's personalize your content